Other Clinical Trial - Preoperative Pembrolizumab Plus Bevacizumab

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT02965248` - Adjuvant Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Versus no HIPEC in Locally Advanced Colorectal Cancer (APEC Study)	Phase 3
	Active, not recruiting	`NCT04301557` - PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer	Phase 2

See also

Status

Clinical Trial

Phase

Recruiting

NCT02965248 - Adjuvant Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Versus no HIPEC in Locally Advanced Colorectal Cancer (APEC Study)

Phase 3

Active, not recruiting

NCT04301557 - PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer

Phase 2

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT05585814
Study type	Interventional
Source	Shanghai Changzheng Hospital
Contact	Haiyang Zhou, MD
Phone	+86 81885615
Email	haiyang1985_1@aliyun.com
Status	Not yet recruiting
Phase	Phase 2
Start date	October 2022
Completion date	October 2025

Preoperative Pembrolizumab Plus Bevacizumab Combined With Chemotherapy in Patients With pMMR/MSS Locally Advanced Colorectal Cancer — COBP

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms